Everest Organics
476.85
+24.80(+5.49%)
Market Cap₹463.08 Cr
PE Ratio66.38
IndustryHealthcare
Company Performance:
1D+5.49%
1M+11.64%
6M+38.78%
1Y+64.72%
5Y+76.45%
View Company Insightsright
More news about Everest Organics
18Feb 25
Everest Organics Secures Korean Drug Master File Approval for Rabeprazole Sodium API
Everest Organics Limited has obtained Drug Master File (DMF) approval from Korean authorities for its Rabeprazole Sodium API on February 18, 2025. This approval allows the company to export the API, used in treating excessive stomach acid conditions, to the South Korean market. The development marks a significant milestone in Everest Organics' international expansion efforts and opens up new revenue opportunities in the Korean pharmaceutical industry.
Everest Organics
476.85
+24.80
(+5.49%)
1 Year Returns:+64.72%
Industry Peers
Sun Pharmaceutical
1,737.00
(-1.08%)
Divis Laboratories
6,496.50
(+0.31%)
Torrent Pharmaceuticals
3,834.30
(+0.37%)
Cipla
1,496.30
(-0.29%)
Dr Reddys Laboratories
1,265.80
(-1.38%)
Lupin
2,107.00
(-0.31%)
Zydus Life Science
917.80
(-1.08%)
Mankind Pharma
2,193.30
(-1.63%)
Aurobindo Pharma
1,211.40
(-0.54%)
Alkem Laboratories
5,566.00
(-0.55%)